Landmark trials such as Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) [98], Action to Control Cardiovascular Risk in Diabetes study [99], ONTARGET®[33] and TRANSCEND®[70] have shown CV and renal benefits with ACE inhibitors or ARBs in patients with T2DM. The gene discussed is ACE; the disease is diabetes mellitus.